This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.
Provectus Pharmaceuticals, Inc., a development- stage oncology and dermatology biopharmaceutical company, has begun a compassionate use program for PV-10 and has made the agent, which is in development as a therapeutic agent for a broad spectrum of cancers, available for select cancer patients.
We care about your feedback. Let us know how we can improve your CancerCompass experience.